Efficacy of ribavirin against malignant glioma cell lines

Ogino,Akiyoshi; Sano,Emiko; Ochiai,Yushi; Yamamuro,Shun; Tashiro,Shinya; Yachi,Kazunari; Ohta,Takashi; Fukushima,Takao; Okamoto,Yutaka; Tsumoto,Kouhei; Ueda,Takuya; Yoshino,Atsuo; Katayama,Yoichi

doi:10.3892/ol.2014.2569

December-2014 Volume 8 Issue 6

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

December-2014 Volume 8 Issue 6

Full Size Image

Article

Efficacy of ribavirin against malignant glioma cell lines

Authors:
- Akiyoshi Ogino
- Emiko Sano
- Yushi Ochiai
- Shun Yamamuro
- Shinya Tashiro
- Kazunari Yachi
- Takashi Ohta
- Takao Fukushima
- Yutaka Okamoto
- Kouhei Tsumoto
- Takuya Ueda
- Atsuo Yoshino
- Yoichi Katayama
View Affiliations / Copyright

Affiliations: Department of Neurological Surgery, Nihon University School of Medicine, Tokyo 173‑8610, Japan, Department of Medical Genome Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Chiba 277‑8562, Japan, New Energy and Industrial Technology Development Organization, Kawasaki 212‑8554, Japan
Pages: 2469-2474
|
Published online on: September 26, 2014

https://doi.org/10.3892/ol.2014.2569
Expand metrics +

Abstract

Ribavirin (1‑β‑D‑ribofuranosy‑1,2,4‑triazole‑ 3‑carboxamide) has been widely administered as an antiviral agent against RNA and DNA viruses. Ribavirin, in combination with interferon, has predominantly been applied in the treatment of the hepatitis C virus infection and its potential antitumor efficacy has recently become a point of interest. The aim of the present study was to evaluate the effect of ribavirin on the growth of malignant glioma cells, to identify novel predictive genes in malignant glioma cells (by analyzing gene expression profiles) and to assess the influence of ribavirin on the cell cycle of malignant glioma cells. The present study evaluated the antitumor efficacy of ribavirin against various malignant glioma cell lines (A‑172, AM‑38, T98G, U‑87MG, U‑138MG, U‑251MG and YH‑13). After culturing the cells in ribavirin‑containing culture medium (final concentration, 0‑1,000 µM) for 72 h, the viable proliferated cells were harvested and counted. The half maximal inhibitory concentration of ribavirin, with regard to the growth of the malignant glioma cell lines, was determined from the concentration of ribavirin required for 50% growth inhibition in comparison to the untreated control cells. Furthermore, the current study identified the genes in which the gene expression levels correlated with the ribavirin sensitivity of the malignant glioma cells lines, using a high‑density oligonucleotide array. Finally, cell cycle analysis was performed on the U‑87MG cell line. It was identified that ribavirin inhibited the growth of all of the malignant glioma cell lines in a dose‑dependent manner, although the ribavirin sensitivity varied between each cell line. Of the extracted genes, PDGFRA demonstrated the strongest positive correlation between gene expression level and ribavirin sensitivity. Cell cycle analysis of the U‑87MG cell line demonstrated that ribavirin treatment induces G0/G1 arrest and thus may be an effective agent for inhibiting malignant glioma cell growth. Therefore, the results of the current study indicate that ribavirin may have potential as a therapeutic agent in the treatment of malignant gliomas.

View Figures

View References

1	Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT and Robins RK: Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science. 177:705–706. 1972.
2	Fried MW, Shiffman ML, Reddy KR, et al: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 347:975–982. 2002.
3	Yamada Y, Natsumeda Y and Weber G: Action of the active metabolites of tiazofurin and ribavirin on purified IMP dehydrogenase. Biochemistry. 27:2193–2196. 1988.
4	Jackson RC, Weber G and Morris HP: IMP dehydrogenase, an enzyme linked with proliferation and malignancy. Nature. 256:331–333. 1975.
5	Assouline S, Culjkovic B, Cocolakis E, et al: Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. Blood. 114:257–260. 2009.
6	Kentsis A, Topisirovic I, Culjkovic B, Shao L and Borden KL: Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap. Proc Natl Acad Sci USA. 101:18105–18110. 2004.
7	Culjkovic B, Topisirovic I and Borden KL: Controlling gene expression through RNA regulons: the role of the eukaryotic translation initiation factor eIF4E. Cell Cycle. 6:65–69. 2007.
8	Borden KL and Culjkovic-Kraljacic B: Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond? Leuk Lymphoma. 51:1805–1815. 2010.
9	Pettersson F, Yau C, Dobocan MC, et al: Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer. Clin Cancer Res. 17:2874–2884. 2011.
10	Yoshino A, Ogino A, Yachi K, et al: Gene expression profiling predicts response to temozolomide in malignant gliomas. Int J Oncol. 36:1367–1377. 2010.
11	Yoshino A, Tashiro S, Ogino A, et al: Gene expression profiles predicting the response to IFN-β and a combination of temozolomide and IFN-β in malignant gliomas. Int J Oncol. 39:529–542. 2011.
12	Heldin CH and Westermark B: Platelet-derived growth factor: mechanism of action and possible in vivo function. Cell Regul. 1:555–566. 1990.
13	Hermanson M, Funa K, Koopmann J, et al: Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor alpha receptor expression in human malignant gliomas. Cancer Res. 56:164–171. 1996.
14	Kleihues P, Burger PC and Aldape KD: Glioblastoma. WHO Classification of Tumours of the Central Nervous System. Louis DN, Ohgaki H, Wiestler OD and Cavenee WK: 4th edition. IARC Press; Lyon, France: pp. 33–49. 2007
15	Gu X, Jones L, Lowery-Norberg M and Fowler M: Expression of eukaryotic initiation factor 4E in astrocytic tumors. Appl Immunohistochem Mol Morphol. 13:178–183. 2005.
16	Kökény S, Papp J, Weber G, Vaszkó T, Carmona-Saez P and Oláh E: Ribavirin acts via multiple pathways in inhibition of leukemic cell proliferation. Anticancer Res. 29:1971–1980. 2009.
17	Vallée S, Fouchier F, Braguer D, Marvaldi J and Champion S: Ribavirin-induced resistance to heat shock, inhibition of the Ras-Raf-1 pathway and arrest in G(1). Eur J Pharmacol. 404:49–62. 2000.
18	Schlosser SF, Schuler M, Berg CP, et al: Ribavirin and alpha interferon enhance death receptor-mediated apoptosis and caspase activation in human hepatoma cells. Antimicrob Agents Chemother. 47:1912–1921. 2003.
19	Stupp R, Mason WP, van den Bent MJ, et al; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005.

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Efficacy of ribavirin against malignant glioma cell lines

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Related Articles